Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amanda Votruba

Pediatrics Elkhorn, NE Medical Doctor

NPI 1497866883 CMS profile 339798

717 N 190Th Plz, Ste. 3100, Elkhorn, NE 68022

Open in the dashboard

General payments

$2,814

142 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Votruba of Elkhorn, NE is reported in the CMS Open Payments database as having received $2,814 across 142 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $362 17
2024 General $651 21
2023 General $451 23
2022 General $553 31
2021 General $246 14
2020 General $205 13
2019 General $346 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Votruba
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Amanda Votruba were reported at $362. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Amanda Votruba Pediatrics median Middle half National median
2019 $346 $86 $31–$183 $163
2020 $205 $49 $22–$110 $114
2021 $246 $68 $27–$158 $132
2022 $553 $77 $30–$173 $149
2023 $451 $88 $33–$190 $160
2024 $651 $94 $34–$206 $164
2025 $362 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $983 34 payments
  2. Tris Pharma Inc $315 17 payments
  3. Merck Sharp & Dohme Corporation $202 12 payments
  4. Ironshore Pharmaceuticals Inc. $161 10 payments
  5. Sanofi Pasteur Inc. $161 9 payments
  6. Pfizer Inc. $147 9 payments
  7. Neos Therapeutics, LP $136 8 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $131 8 payments
  9. Corium, Inc. $77 4 payments
  10. Novartis Pharmaceuticals Corporation $70 4 payments
  11. Other $430 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,814 142 payments
Products named General payments · program years 2019–2025
  1. Qelbree Viloxazine Hydrochloride $582 16 payments
  2. QELBREE Psychology $402 18 payments
  3. GARDASIL 9 $190 11 payments
  4. VAXELIS $174 10 payments
  5. Dyanavel XR $157 8 payments
  6. ROTATEQ $155 9 payments
  7. EUCRISA $120 7 payments
  8. VAXNEUVANCE $120 7 payments
  9. Adzenys XR-ODT $120 7 payments
  10. JORNAY PM $111 7 payments
  11. Other $1,664 100 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

142 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record